Sec Form 4 Filing - ARMISTICE CAPITAL, LLC @ ReShape Lifesciences Inc. - 2021-06-28

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person ARMISTICE CAPITAL, LLC 2. Issuer Name and Ticker or Trading Symbol ReShape Lifesciences Inc. [ RSLS] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 510 MADISON AVENUE, 7TH FLOOR, 3. Date of Earliest Transaction (MM/DD/YY) 06/28/2021 (Street) NEW YORK, NY10022 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 06/28/2021 X( 2 )( 3 ) 1,479,713 A 1,572,253 ( 2 ) ( 3 ) D ( 1 ) Common Stock 06/28/2021 X( 2 )( 3 ) 0 A $ 0 1,572,253 ( 2 ) ( 3 ) I See Footnote 1 Common Stock 06/28/2021 X( 2 )( 3 ) 1,479,713 A 3,051,966 ( 2 ) ( 3 ) D ( 1 ) Common Stock 06/28/2021 X( 2 )( 3 ) 0 A $ 0 3,051,966 ( 2 ) ( 3 ) I See Footnote 1 Common Stock 06/28/2021 X( 2 )( 3 ) 676,440 A 3,728,406 ( 2 ) ( 3 ) D ( 1 ) Common Stock 06/28/2021 X( 2 )( 3 ) 0 A $ 0 3,728,406 ( 2 ) ( 3 ) I See Footnote 1 Common Stock 06/28/2021 X( 2 )( 3 ) 676,440 A 4,404,846 ( 2 ) ( 3 ) D ( 1 ) Common Stock 06/28/2021 X( 2 )( 3 ) 0 A $ 0 4,404,846 ( 2 ) ( 3 ) I See Footnote 1 Common Stock 06/28/2021 X( 2 )( 3 ) 2,254,800 A 6,659,646 ( 2 ) ( 3 ) D ( 1 ) Common Stock 06/28/2021 X( 2 )( 3 ) 0 A $ 0 6,659,646 ( 2 ) ( 3 ) I See Footnote 1 Common Stock 06/28/2021 X( 2 )( 3 ) 563,700 A 7,223,346 ( 2 ) ( 3 ) D ( 1 ) Common Stock 06/28/2021 X( 2 )( 3 ) 0 A $ 0 7,223,346 ( 2 ) ( 3 ) I See Footnote 1

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Series A Warrants ( 4 ) 06/28/2021 X( 2 )( 3 ) 1,479,713 ( 4 ) ( 4 ) COMMON STOCK 1,479,713 ( 2 ) ( 3 ) 0 D ( 1 ) Series A Warrants ( 4 ) 06/28/2021 X( 2 )( 3 ) 0 ( 4 ) ( 4 ) COMMON STOCK 0 ( 2 ) ( 3 ) 0 I See Footnote 1 Series E Warrants ( 5 ) 06/28/2021 X( 2 )( 3 ) 1,479,713 ( 5 ) ( 5 ) COMMON STOCK 1,479,713 ( 2 ) ( 3 ) 0 D ( 1 ) Series E Warrants ( 5 ) 06/28/2021 X( 2 )( 3 ) 0 ( 5 ) ( 5 ) COMMON STOCK 0 ( 2 ) ( 3 ) 0 I See Footnote 1 Series G Warrants ( 6 ) 06/28/2021 X( 2 )( 3 ) 676,440 ( 6 ) ( 6 ) COMMON STOCK 676,440 ( 2 ) ( 3 ) 0 D ( 1 ) Series G Warrants ( 6 ) 06/28/2021 X( 2 )( 3 ) 0 ( 6 ) ( 6 ) COMMON STOCK 0 ( 2 ) ( 3 ) 0 I See Footnote 1 Series G Warrants ( 7 ) 06/28/2021 X( 2 )( 3 ) 676,440 ( 7 ) ( 7 ) COMMON STOCK 676,440 ( 2 ) ( 3 ) 0 D ( 1 ) Series G Warrants ( 7 ) 06/28/2021 X( 2 )( 3 ) 0 ( 7 ) ( 7 ) COMMON STOCK 0 ( 2 ) ( 3 ) 0 I See Footnote 1 Warrant ( 8 ) 06/28/2021 X( 2 )( 3 ) 2,254,800 ( 8 ) ( 8 ) COMMON STOCK 2,254,800 ( 2 ) ( 3 ) 0 D ( 1 ) Warrant ( 8 ) 06/28/2021 X( 2 )( 3 ) 0 ( 8 ) ( 8 ) COMMON STOCK 0 ( 2 ) ( 3 ) 0 I See Footnote 1 Warrant ( 9 ) 06/28/2021 X( 2 )( 3 ) 563,700 ( 9 ) ( 9 ) COMMON STOCK 563,700 ( 2 ) ( 3 ) 0 D ( 1 ) Warrant ( 9 ) 06/28/2021 X( 2 )( 3 ) 0 ( 9 ) ( 9 ) COMMON STOCK 0 ( 2 ) ( 3 ) 0 I See Footnote 1

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other ARMISTICE CAPITAL, LLC 510 MADISON AVENUE, 7TH FLOOR NEW YORK, NY10022 X Boyd Steven C/O ARMISTICE CAPITAL, LLC 510 MADISON AVENUE, 7TH FLOOR NEW YORK, NY10022 X Signatures Armistice Capital, LLC By: /s/ Steven Boyd, Managing Member 06/29/2021 Signature of Reporting Person Date /s/ Steven Boyd 06/29/2021 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The reported securities (the "Shares") of ReShape Lifesciences Inc. (the "Issuer") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the "Master Fund"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC ("Armistice Capital"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital ("Mr. Boyd", and together with Armistice Capital, the "Reporting Persons"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. ( 2 )On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the "Inducement Agreement"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the "Existing Warrants") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the "Warrant Exercise"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants ("New Warrants") ( 3 )[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% ("Beneficial Ownership Limitation")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance). The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement. ( 4 )The terms of these Series A Warrants are substantially similar to the Series A Warrants previously listed on the Reporting Persons' Form 4 dated September 16, 2020 with respect to ReShape Weightloss Inc. (then-named Reshape Lifesciences Inc.) ("Pre-Merger ReShape"), as modified by the Agreement and Plan of Merger, dated as of January 19, 2021, by and among the Issuer, Optimus Merger Sub, Inc., and Pre-Merger ReShape (incorporated by reference to Exhibit 2.1 the Form 8-K filed by Pre-Merger ReShape with the SEC on June 15, 2021) (the "Merger Agreement"). ( 5 )The terms of these Series E Warrants are substantially similar to the Series E Warrants previously listed on the Reporting Persons' Form 4 dated September 16, 2020 with respect to Pre-Merger ReShape, as modified by the Merger Agreement. ( 6 )The terms of these Series G Warrants are substantially similar to the New Series G Warrants previously listed on the Reporting Persons' Form 4 dated September 16, 2020 with respect to Pre-Merger ReShape, as modified by the Merger Agreement. ( 7 )The terms of these Series G Warrants ("Additional Series G Warrants") are substantially similar to the Existing Series G Warrants previously listed on the Reporting Persons' Form 4 dated September 16, 2020 with respect to Pre-Merger ReShape, as modified by the Merger Agreement. ( 8 )The terms of this Warrant are substantially similar to the terms of the Additional Series G Warrants, as modified by the Third Amendment to Credit Agreement, dated December 16, 2020 by and between Pre-Merger ReShape and the Master Fund (incorporated by reference to Exhibit 10.1 to the Form 8-K filed by Pre-Merger ReShape with the SEC on December 22, 2020) and the Merger Agreement. ( 9 )The terms of this Warrant are substantially similar to the terms of the Additional Series G Warrants, as modified by the Fourth Amendment to Credit Agreement, dated January 19, 2021 by and between Pre-Merger ReShape and the Master Fund (incorporated by reference to Exhibit 10.3 to the Form 8-K filed by Pre-Merger ReShape with the SEC on January 20, 2021) and the Merger Agreement.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.